Mark T Iwicki
CIK 1415537 · Chief Executive Officer · last filed 2026-01-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$702.1K
Companies
11
Total Filings
77
Lifetime Open-Market Net
$131.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IKT | Chief Executive Officer | — | $1.67 | — | $0 | 4 | 2026-01-07 |
| Merus N.V. (MRUS) Delisted | Director | 0 | $90.00 | $0 | $0 | 8 | 2025-12-12 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $0 | 7 | 2025-12-09 |
| QTTB | Director | — | $12.64 | — | $0 | 3 | 2025-10-27 |
| KALA | Director | 103,540 | $2.63 | $272.3K | -$488.3K | 25 | 2025-10-24 |
| Third Harmonic Bio, Inc. (THRD) Delisted | Director | — | $5.38 | — | $0 | 4 | 2024-06-10 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 4 | 2024-06-07 |
| PULM | Director | 307,000 | $1.40 | $429.8K | $0 | 8 | 2021-02-01 |
| COLL | Director | 0 | $34.64 | $0 | $300.0K | 7 | 2020-10-14 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | Director | 20,000 | — | — | $320.0K | 1 | 2015-08-11 |
| SEPRACOR INC /DE/ (SEPR) Delisted | EVP & Chief Commercial Officer | 122,334 | — | — | $0 | 4 | 2009-10-19 |
Recent Filings · Page 3 of 8
77 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-07 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-03 | KALA | Sell (S) | −7,392 | -$45.0K | EDGAR |
| 2024-05-09 | Merus N.V. (MRUS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-27 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2024-01-05 | KALA | Mixed | +9,761 | -$30.5K | EDGAR |
| 2023-06-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | KALA | Grant (A) | +158,873 | $0 | EDGAR |
| 2023-06-12 | Merus N.V. (MRUS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | Third Harmonic Bio, Inc. (THRD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.